Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a swiss university hospital and a nationwide predictive model

Andrew Stewardson, Carolina Fankhauser, Giulia De Angelis, Peter Rohner, Edith Safran, Jacques Schrenzel, Didier Pittet, Stephan Harbarth

Research output: Contribution to journalArticleResearchpeer-review

32 Citations (Scopus)

Abstract

objective. To obtain an unbiased estimate of the excess hospital length of stay (LOS) and cost attributable to extended-spectrum β-lactamase (ESBL) positivity in bloodstream infections (BSIs) due to Enterobacteriaceae. design. Retrospective cohort study. setting. A 2,200-bed academic medical center in Geneva, Switzerland. patients. Patients admitted during 2009. methods. We used multistate modeling and Cox proportional hazards models to determine the excess LOS and adjusted end-of-LOS hazard ratio (HR) for ESBL-positive and ESBL-negative BSI. We estimated economic burden as the product of excess LOS and average bed-day cost. Patient-level accounting data provided a complementary analysis of economic burden. A predictive model was fitted to national surveillance data. results. Thirty ESBL-positive and 96 ESBL-negative BSI cases were included. The excess LOS attributable to ESBL-positive and ESBL-negative BSI was 9.4 (95% confidence interval [CI], 0.4-18.4) and 2.6 (95% CI, 0.7-5.9) days, respectively. ESBL positivity was therefore associated with 6.8 excess days and CHF 9,473 per BSI. The adjusted end-of-LOS HRs for ESBL-positive and ESBL-negative BSI were 0.62 (95% CI, 0.43-0.89) and 0.90 (95% CI, 0.74-1.10), respectively. After reimbursement, the average financial loss per acute care episode in ESBL-positive BSI, ESBL-negative BSI, and control cohorts was CHF 48,674, 48,131, and 13,532, respectively. Our predictive model estimated that the nationwide cost of third-generation cephalosporin resistance would increase from CHF 2,084,000 in 2010 to CHF 3,526,000 in 2015. conclusions. This is the first hospital-wide analysis of excess LOS attributable to ESBL positivity determined using multistate modeling to avoid time-dependent bias. These results may inform health-economic evaluations of interventions targeting ESBL control.

Original languageEnglish
Pages (from-to)133-143
Number of pages11
JournalInfection Control and Hospital Epidemiology
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 2013
Externally publishedYes

Cite this

Stewardson, Andrew ; Fankhauser, Carolina ; De Angelis, Giulia ; Rohner, Peter ; Safran, Edith ; Schrenzel, Jacques ; Pittet, Didier ; Harbarth, Stephan. / Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a swiss university hospital and a nationwide predictive model. In: Infection Control and Hospital Epidemiology. 2013 ; Vol. 34, No. 2. pp. 133-143.
@article{449bc49046d94190aea1fdc3abcb1b48,
title = "Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a swiss university hospital and a nationwide predictive model",
abstract = "objective. To obtain an unbiased estimate of the excess hospital length of stay (LOS) and cost attributable to extended-spectrum β-lactamase (ESBL) positivity in bloodstream infections (BSIs) due to Enterobacteriaceae. design. Retrospective cohort study. setting. A 2,200-bed academic medical center in Geneva, Switzerland. patients. Patients admitted during 2009. methods. We used multistate modeling and Cox proportional hazards models to determine the excess LOS and adjusted end-of-LOS hazard ratio (HR) for ESBL-positive and ESBL-negative BSI. We estimated economic burden as the product of excess LOS and average bed-day cost. Patient-level accounting data provided a complementary analysis of economic burden. A predictive model was fitted to national surveillance data. results. Thirty ESBL-positive and 96 ESBL-negative BSI cases were included. The excess LOS attributable to ESBL-positive and ESBL-negative BSI was 9.4 (95{\%} confidence interval [CI], 0.4-18.4) and 2.6 (95{\%} CI, 0.7-5.9) days, respectively. ESBL positivity was therefore associated with 6.8 excess days and CHF 9,473 per BSI. The adjusted end-of-LOS HRs for ESBL-positive and ESBL-negative BSI were 0.62 (95{\%} CI, 0.43-0.89) and 0.90 (95{\%} CI, 0.74-1.10), respectively. After reimbursement, the average financial loss per acute care episode in ESBL-positive BSI, ESBL-negative BSI, and control cohorts was CHF 48,674, 48,131, and 13,532, respectively. Our predictive model estimated that the nationwide cost of third-generation cephalosporin resistance would increase from CHF 2,084,000 in 2010 to CHF 3,526,000 in 2015. conclusions. This is the first hospital-wide analysis of excess LOS attributable to ESBL positivity determined using multistate modeling to avoid time-dependent bias. These results may inform health-economic evaluations of interventions targeting ESBL control.",
author = "Andrew Stewardson and Carolina Fankhauser and {De Angelis}, Giulia and Peter Rohner and Edith Safran and Jacques Schrenzel and Didier Pittet and Stephan Harbarth",
year = "2013",
month = "2",
doi = "10.1086/669086",
language = "English",
volume = "34",
pages = "133--143",
journal = "Infection Control and Hospital Epidemiology",
issn = "0899-823X",
publisher = "The University of Chicago Press",
number = "2",

}

Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a swiss university hospital and a nationwide predictive model. / Stewardson, Andrew; Fankhauser, Carolina; De Angelis, Giulia; Rohner, Peter; Safran, Edith; Schrenzel, Jacques; Pittet, Didier; Harbarth, Stephan.

In: Infection Control and Hospital Epidemiology, Vol. 34, No. 2, 02.2013, p. 133-143.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a swiss university hospital and a nationwide predictive model

AU - Stewardson, Andrew

AU - Fankhauser, Carolina

AU - De Angelis, Giulia

AU - Rohner, Peter

AU - Safran, Edith

AU - Schrenzel, Jacques

AU - Pittet, Didier

AU - Harbarth, Stephan

PY - 2013/2

Y1 - 2013/2

N2 - objective. To obtain an unbiased estimate of the excess hospital length of stay (LOS) and cost attributable to extended-spectrum β-lactamase (ESBL) positivity in bloodstream infections (BSIs) due to Enterobacteriaceae. design. Retrospective cohort study. setting. A 2,200-bed academic medical center in Geneva, Switzerland. patients. Patients admitted during 2009. methods. We used multistate modeling and Cox proportional hazards models to determine the excess LOS and adjusted end-of-LOS hazard ratio (HR) for ESBL-positive and ESBL-negative BSI. We estimated economic burden as the product of excess LOS and average bed-day cost. Patient-level accounting data provided a complementary analysis of economic burden. A predictive model was fitted to national surveillance data. results. Thirty ESBL-positive and 96 ESBL-negative BSI cases were included. The excess LOS attributable to ESBL-positive and ESBL-negative BSI was 9.4 (95% confidence interval [CI], 0.4-18.4) and 2.6 (95% CI, 0.7-5.9) days, respectively. ESBL positivity was therefore associated with 6.8 excess days and CHF 9,473 per BSI. The adjusted end-of-LOS HRs for ESBL-positive and ESBL-negative BSI were 0.62 (95% CI, 0.43-0.89) and 0.90 (95% CI, 0.74-1.10), respectively. After reimbursement, the average financial loss per acute care episode in ESBL-positive BSI, ESBL-negative BSI, and control cohorts was CHF 48,674, 48,131, and 13,532, respectively. Our predictive model estimated that the nationwide cost of third-generation cephalosporin resistance would increase from CHF 2,084,000 in 2010 to CHF 3,526,000 in 2015. conclusions. This is the first hospital-wide analysis of excess LOS attributable to ESBL positivity determined using multistate modeling to avoid time-dependent bias. These results may inform health-economic evaluations of interventions targeting ESBL control.

AB - objective. To obtain an unbiased estimate of the excess hospital length of stay (LOS) and cost attributable to extended-spectrum β-lactamase (ESBL) positivity in bloodstream infections (BSIs) due to Enterobacteriaceae. design. Retrospective cohort study. setting. A 2,200-bed academic medical center in Geneva, Switzerland. patients. Patients admitted during 2009. methods. We used multistate modeling and Cox proportional hazards models to determine the excess LOS and adjusted end-of-LOS hazard ratio (HR) for ESBL-positive and ESBL-negative BSI. We estimated economic burden as the product of excess LOS and average bed-day cost. Patient-level accounting data provided a complementary analysis of economic burden. A predictive model was fitted to national surveillance data. results. Thirty ESBL-positive and 96 ESBL-negative BSI cases were included. The excess LOS attributable to ESBL-positive and ESBL-negative BSI was 9.4 (95% confidence interval [CI], 0.4-18.4) and 2.6 (95% CI, 0.7-5.9) days, respectively. ESBL positivity was therefore associated with 6.8 excess days and CHF 9,473 per BSI. The adjusted end-of-LOS HRs for ESBL-positive and ESBL-negative BSI were 0.62 (95% CI, 0.43-0.89) and 0.90 (95% CI, 0.74-1.10), respectively. After reimbursement, the average financial loss per acute care episode in ESBL-positive BSI, ESBL-negative BSI, and control cohorts was CHF 48,674, 48,131, and 13,532, respectively. Our predictive model estimated that the nationwide cost of third-generation cephalosporin resistance would increase from CHF 2,084,000 in 2010 to CHF 3,526,000 in 2015. conclusions. This is the first hospital-wide analysis of excess LOS attributable to ESBL positivity determined using multistate modeling to avoid time-dependent bias. These results may inform health-economic evaluations of interventions targeting ESBL control.

UR - http://www.scopus.com/inward/record.url?scp=84872202088&partnerID=8YFLogxK

U2 - 10.1086/669086

DO - 10.1086/669086

M3 - Article

VL - 34

SP - 133

EP - 143

JO - Infection Control and Hospital Epidemiology

JF - Infection Control and Hospital Epidemiology

SN - 0899-823X

IS - 2

ER -